Related Experiment Video

Updated: Apr 15, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K

New drugs for the treatment of non-Hodgkin lymphomas

Sonali M Smith1

  • 1Section of Hematology/Oncology, Lymphoma Program, The University of Chicago, Chicago, IL 60637, USA. smsmith@medicine.bsd.uchicago.edu.

Chinese Clinical Oncology
|April 6, 2015
PubMed

Insights

New targeted therapies are emerging for Non-Hodgkin lymphomas (NHL), including B-cell receptor (BCR) and PI3K inhibitors. These novel agents aim to improve treatment efficacy and reduce toxicity for better patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Non-Hodgkin lymphomas (NHL) are heterogeneous cancers of B-cell or T-cell origin.
  • While historically chemosensitive, NHL treatment is evolving towards targeted therapies.
  • Recent advances focus on understanding NHL biology to develop more precise treatments.

Purpose of the Study:

  • To review emerging targeted agents for Non-Hodgkin lymphomas.
  • To discuss novel therapeutic strategies based on NHL molecular pathways.
  • To highlight the potential of new agents to improve efficacy and toxicity profiles.

Main Methods:

  • Review of recent clinical data and approvals for novel NHL agents.
  • Analysis of targeted therapies including BCR and PI3K inhibitors.
  • Exploration of upcoming drug classes like SINE, PD1 inhibitors, and apoptosis inhibitors.

Main Results:

  • Several new targeted agents are approved or in development for NHL.
  • Inhibitors of B-cell receptor (BCR) and PI3K signaling show promise.
  • Other promising agents include SINE, PD1 inhibitors, and apoptosis inhibitors.

Conclusions:

  • The landscape of NHL treatment is rapidly advancing with novel targeted therapies.
  • Personalized application of these new agents is crucial for the next generation of clinical trials.
  • Improved efficacy and reduced toxicity are anticipated with these biologically rational treatments.
Keywords:
B-cell receptor (BCR) inhibitorsclinical trialslymphomatargeted agents

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K